The ALPS Medical Breakthroughs ETF (SBIO) is a passively managed exchange-traded fund that seeks to track, before fees and expenses, the S-Network Medical Breakthroughs Index. The index is composed of small- and mid-cap biotechnology and pharmaceutical companies listed on U.S. exchanges with one or more drug candidates in Phase II or Phase III FDA clinical trials, with constituent market capitalizations generally between $200 million and $5 billion.
The fund holds approximately 90–100 securities and is concentrated almost entirely in the healthcare sector, specifically biotechnology and pharmaceuticals. Its largest positions include Crinetics Pharmaceuticals (CRNX), Apogee Therapeutics (APGE), CG Oncology (CGON), and ACADIA Pharmaceuticals (ACAD), alongside smaller weightings in Dianthus Therapeutics, Edgewise Therapeutics, Oruka Therapeutics, and Travere Therapeutics. SBIO carries a 0.50% net expense ratio and net assets under $200 million, making it a relatively small, specialized fund within the healthcare ETF category. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.
Biotechnology remains one of the most capital-intensive and innovation-driven segments of the equity market. Clinical-stage companies typically generate little or no revenue, instead funding research through equity issuance, partnerships, and licensing deals. This structure makes small- and mid-cap biotech highly sensitive to the cost of capital: when interest rates rise, the present value of distant future cash flows falls and financing becomes more expensive, pressuring valuations.
The macro backdrop has reinforced this dynamic in recent months. The Federal Reserve raised its benchmark rate in September, its first increase since 2023, while oil-driven inflation kept the 10-year U.S. Treasury yield elevated near its highest level since 2007. These conditions weigh most heavily on pre-revenue, clinical-stage names. At the same time, structural innovation in oncology, rare disease, genetic medicines, and metabolic health continues to attract capital, and large pharmaceutical firms retain substantial M&A appetite for late-stage assets ahead of a sizable patent cliff. Drug-pricing legislation and FDA review timelines add further regulatory uncertainty.
SBIO's recent trajectory illustrates the sector's volatility. After climbing to a 52-week high near $70 in August, the fund corrected sharply through September and October, falling roughly 25% to the low-$50s as rate-sensitive valuations repriced following the Fed's tightening and the surge in Treasury yields. A subsequent stabilization in yields and renewed appetite for oversold biotech names supported a recovery of roughly 9% over the trailing month, though the fund remains about 17% below its level from three months earlier.
The drawdown was broad-based rather than driven by any single holding, reflecting sector-wide de-risking in the face of higher discount rates. The partial rebound has been supported by clinical data announcements and a revival of M&A interest in later-stage assets, which tends to lift the entire small-cap biotech complex rather than only the directly affected names. This pattern underscores the index's inherent concentration risk and its sensitivity to shifts in investor sentiment. From what I see, this volatility is typical for the sector but worth monitoring closely.
Several structural factors are likely to shape SBIO through the remainder of 2026. The trajectory of Federal Reserve policy and inflation will remain central, since lower rates would ease financing costs and support valuations for cash-burning biotechs. Clinical trial readouts and FDA approval decisions across the portfolio's Phase II and Phase III assets will drive idiosyncratic performance, while large-cap pharmaceutical M&A could provide recurring catalysts for the small-cap names in the index.
Investors should also monitor biotech financing conditions, including initial public offering and follow-on equity activity, which influence the sector's ability to fund research. Regulatory developments around drug pricing and FDA review standards, along with broader risk appetite and capital flows into sector ETFs, will further shape the environment. The fund's concentrated, high-volatility profile means these factors can produce rapid, sizable swings in either direction.
I often rely on Tickeron’s AI-powered platforms when analyzing specialized ETFs like this one. The AI Screener allows me to scan thousands of securities using technical indicators, fundamentals, volatility measures, AI-generated signals, market trends, price patterns, and customizable filters. It helps surface relevant comparisons and opportunities more efficiently than manual methods. Investors seeking to refine their research across sectors, industries, and market conditions can explore the platform's capabilities through the AI Screener.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
The RSI Oscillator for SBIO moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 27 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on SBIO as a result. In 75 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for SBIO just turned positive on October 20, 2026. Looking at past instances where SBIO's MACD turned positive, the stock continued to rise in 46 of 51 cases over the following month. The odds of a continued upward trend are 90%.
Following a +9.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where SBIO advanced for three days, in 277 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Aroon Indicator entered an Uptrend today. In 211 of 230 cases where SBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 63 cases where SBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
SBIO moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
SBIO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows